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Background & Aims: Liver resection (LR) in patients with hepatocellular carcinoma (HCC) and clinically significant portal
hypertension (CSPH) defined as a hepatic venous pressure gradient (HVPG) >−10 mmHg is not encouraged. Here, we reap-
praised the outcomes of patients with cirrhosis and CSPH who underwent LR for HCC in highly specialised liver centres.
Methods: This was a retrospective multicentre study from 1999 to 2019. Predictors for postoperative liver decompensation
and textbook outcomes were identified.
Results: In total, 79 patientswith amedian age of 65 yearswere included. The Child-Pugh gradewasA in 99% of patients, and the
median model for end-stage liver disease (MELD) score was 8. The median HVPG was 12 mmHg. Major hepatectomies and
laparoscopieswere performed in 28% and34%of patients, respectively. Ninety-daymortality and severemorbidity rateswere6%
and 27%, respectively. Postoperative and persistent liver decompensation occurred in 35% and 10% of patients at 3 months.
Predictors of liver decompensation included increased preoperative HVPG (p = 0.004), increased serum total bilirubin (p = 0.02),
andopen approach (p = 0.03). Of the patients, 34% achieveda textbook outcome, ofwhich the laparoscopic approachwas the sole
predictor (p = 0.004). The 5-year overall survival and recurrence-free survival rates were 55% and 43%, respectively.
Conclusions: Patients with cirrhosis, HCC and HVPG >−10 mmHg can undergo LR with acceptable mortality, morbidity, and
liver decompensation rates. The laparoscopic approach was the sole predictor of a textbook outcome.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Liver resection (LR) is one of the few first-line curative options
for patients with cirrhosis, very-early/early-stage hepatocellular
carcinoma (HCC) and preserved liver function.1
In this setting of LR, portal hypertension (PHT) has been asso-
ciated with increased postoperative morbidity and liver decom-
pensation,2,3 which led to PHT being considered a formal
contraindication for LR.4 Recently, updated guidelines from the
European Association for the Study of the Liver (EASL) opened the
door to LR for HCC in patients with PHT by endorsing a risk algo-
rithm for postoperative liver decompensation.5 This algorithm
includes the hierarchical interaction of three preoperative vari-
ables in the following order: presence of PHT; extent of resection;
andmodel for end-stage liver disease (MELD) score. However, this
algorithmwas determined from a series of LRs performedwith an
open approach, in which PHT was defined by the presence ofKeywords: Hepatectomy; Hepatic venous pressure gradient; Clinically significant
portal hypertension; Postoperative liver decompensation; Textbook outcome.
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approach decreases the risk of liver surgery,6–9 and the actual
measurement of the hepatic venous pressure gradient (HVPG),
which is the current gold-standard method for ascertaining clin-
ically significant PHT (CSPH, defined as HVPG >−10 mm Hg), high-
lights the limited sensitivity and specificity of indirect signs.10,11
This background motivated the creation of a consortium of spe-
cialised liver centres in which all non-surgical and surgical ap-
proaches, including laparoscopy, are available and where HVPG
measurement is routine in the preoperative assessment before LR for
HCC in patients with cirrhosis. Here, we assessed the short-term and
oncological outcomesof selectedpatientswith CSPHafter LR forHCC,
taking into account patient-oriented outcomes. Reasonable results,
namely a reasonable rate of postoperative liver decompensation and
the possibility of achieving a textbook outcome, including in techni-
cally difficult cases,wouldpromote reconsiderationof the indications
for resection in theselectedgroupofpatientswithcirrhosis andCSPH.Materials and methods
Study design
The study population included all consecutive patients with
cirrhosis and preoperative CSPH, as assessed by HVPG
Research articlemeasurement, who underwent LR for HCC between November
1999 and March 2019 in three Western liver centres (Henri Mon-
dor Hospital, Créteil, France; Universitari Dr Josep Trueta Hospital,
Girona, Spain; and Universitari de Bellvitge Hospital, Barcelona,
Spain).
The primary endpoint was to assess the safety of LR in pa-
tients with preoperative CSPH, evaluated as 90-day mortality
and morbidity. Secondary endpoints included the occurrence of
postoperative liver decompensation, a textbook outcome, and
long-term oncological outcomes. The study protocol was
designed according to the ethical guidelines of the 1975 Decla-
ration of Helsinki and approved by the institutional review
boards of the three centres.
Study population
The diagnosis of HCC relied on the acknowledged diagnostic
criteria of HCC. First, to be considered potential candidates for LR,
patients had to fulfil the following criteria: no previous history of
ascites, variceal rupture, or spontaneous encephalopathy; no
prohibitive comorbidities; Child-Pugh class A liver function or
class B, provided this was because of biliary obstruction; and a
plan for a complete macroscopic resection combined with a
sufficient future remnant liver volume upon preoperative
computed tomography (CT) volumetric assessment [following
percutaneous portal vein embolisation (PVE) whenever
needed12]. The alpha-fetoprotein (AFP) level was not considered
in the decision for surgery. Second, all of the above-selected
patients underwent preoperative PHT assessment, including
transjugular HVPG measurement complying with technical rec-
ommendations,13 CT and upper gastrointestinal endoscopy.
Briefly, within the 2 weeks before surgery, HVPG measurements
were performed in fasting conditions under local anaesthesia.
The right jugular vein was canalised under ultrasonographic
guidance. A 7-French balloon-tipped catheter (‘Fogarty’ Edwards
Lifesciences LLC, Irvine, CA, USA) was guided into the main right
or middle hepatic vein for measurements of wedged and free
HVPs to calculate the HVPG. All measurements were taken in
triplicate and averaged to obtain the baseline HVPG. HVPG >−10
mmHg indicated the presence of CSPH14 regardless of the pres-
ence of oesophageal varices, thrombopenia, or splenomegaly.
The presence of oesophageal varices or the coexistence of a
platelet count <109/L and splenomegaly >120 mm in diameter
were considered surrogates of CSPH.15 At this stage, patients
with HVPG >−30 mmHg were arbitrarily excluded from resection.
The indications for surgery, planned resection, and the chosen
approach were homogenous across centres (see later) and
decided during board meetings at each liver centre.
Surgical approach and complexity of liver resection
Laparoscopic approach, repeat hepatectomy, or anatomical
resection were performed whenever possible. The laparoscopic
approach was chosen according to the guidelines of the World
Consensus Conference on Laparoscopic Surgery.16,17
The technical difficulty of each procedure was evaluated
based on a 3-level classification validated for both the laparo-
scopic and open approaches.18,19 Briefly, this comprised three
levels of technical difficulty [low, wedge resection and left lateral
sectionectomy; moderate, anterolateral segmentectomy (from
segments II to VI) and left hepatectomy; and high: poster-
osuperior segmentectomy (segments VII, VIII, and I), right andJHEP Reports 2021extended right hepatectomy, right posterior sectionectomy,
central hepatectomy, and extended left hepatectomy].
Major resection was defined as resection >−3 contiguous
Couinaud’s segments. Morbidity was evaluated according to the
comprehensive complication index described by Slankamenac
et al.20 (available at www.assessurgery.com/calculator_single/).
Severe morbidity was defined by a Comprehensive Complication
Index (CCI) >−26.2, which refers to 1 complication of Clavien-
Dindo grade IIIa.21
Liver complications (grade A or higher) included liver fail-
ure,22 bile leakage,23 and haemorrhage,24 as defined by the In-
ternational Study Group on Liver Surgery. Postoperative ascites
and encephalopathy were defined based on the definition of
Moore et al.25 and Vilstrup et al.,26 respectively. Non-liver com-
plications included cardiopulmonary and infectious complica-
tions and acute kidney injury.27
Three binary composite endpoints were used: postoperative
liver decompensation; persistent liver decompensation at 3
months; and textbook outcome. Postoperative liver decom-
pensation was defined as present when at least 1 of the
following complications occurred within 3 months after
resection: liver failure; ascites; or encephalopathy. Persistent
liver decompensation was defined as present when at least 1 of
the following three liver complications occurred at 3 months
after resection: jaundice and/or ascites and/or encephalopa-
thy.28 A textbook outcome was achieved when all 6 of the
following criteria were met: no perioperative transfusion; no
major postoperative complications (CCI <26.2); no mortality
within 90 days or during the hospital stay; hospital stay <50th
percentile of the total cohort (<−8 days); R0 resection (>−1 mm),
and no readmission.29–32
Postoperative mortality included any death within 90 days or
during hospitalisation for LR. Readmission included any hospi-
talisation occurring after discharge within 90 days following LR.
Follow-up
Patients were followed up every 4 months for the first 2 years
and every 6 months thereafter. Tumour recurrence and liver
status were monitored, and patients were treated according to
disease presentation. HCC recurrence, persistent liver decom-
pensation, or death were recorded as major impact events.
Follow-up for this study was completed on 11 April 2020.
Statistical analysis
Continuous variables were expressed as the median and 25–75th
IQR. Categorical variables were expressed as numbers and per-
centages. Student’s t test, the Mann-Whitney U test and Fisher’s
exact test were used as appropriate.
Overall survival was defined as the period between the date
of hepatectomy and the date of death or last follow-up. Recur-
rence-free survival was defined as the period between the date
of hepatectomy and the date of first recurrence or death.
Two multivariate regression logistic analyses were performed
to identify the independent predictors of: (1) postoperative liver
decompensation; and (2) textbook outcome. All pre- and intra-
operative variables associated with these two latter composite
endpoints in the univariable analysis (p <0.1) were included in
the multivariate analysis. Statistical analysis was performed us-
ing Statview version 5.0 (SAS Institute, Inc., Cary, NC, USA). The
present study complied with RECORD guidelines.332vol. 3 j 100190
Table 2. Surgical procedures and intraoperative characteristics.
Variable Study population (79 patients)
Portal vein embolisation 5 (6)
Repeat hepatectomy 2 (3)
Laparoscopic hepatectomy 27 (34)
Anatomical resection* 45 (57)
Type of surgical procedure
Wedge resection 34 (43)
Segmentectomy 17 (22)
Bisegmentectomy 14 (18)
Major hepatectomy† 14 (18)
Left-sided hepatectomy 5 (6)
Right-sided hepatectomy 9 (11)
Multiple hepatectomies 6 (8)
Associated procedures‡ 8 (10)
Technical difficulty grade
(low/moderate/high)
44 (56)/14 (18)/21 (27)
Inflow clamping 66 (84)
Duration of inflow clamping (min) 30 (10–48)
Duration of operation (min) 240 (180–300)
Blood loss (ml) 200 (110–611)
Blood transfusion 11 (14)
Red blood cell units (mean ± SD) 1.3 ± 0.8
Intraoperative mortality 0 (0)
Results are presented as median (IQR) or n (%), unless indicated otherwise.
* Defined as any type of systematic resection of the portal areas based on Couinaud
classification.
† Major hepatectomy defined by resection >3 Couinaud segments.Results
Study population
During the study period, a total of 375 consecutive patients with
HCC and liver cirrhosis who had LRs underwent HVPG assess-
ment before surgery. The study population comprised 79 (21%)
patients with preoperative CSPH, namely, those with HVPG >−10
mmHg. The baseline characteristics of the study population are
shown in Table 1. Viral infection (63%) was the most common
cause of cirrhosis. The Child-Pugh grade of 78 (99%) patients was
A, and the median MELD score was 8 (IQR: 6–9). The median
HVPG was 12 mmHg (IQR: 11–15, range 10–26 mmHg). Indirect
signs of CSPH were observed in 31 (39%) patients: oesophageal
varices were present in 26 (33%) and splenomegaly and throm-
bopenia in 12 (15%). Only 7 (9%) patients met all the surrogate
criteria for CSPH, and 28 (35%) patients had none of them. Tu-
mours presented as a single nodule in 66 patients (84%), and the
median size of the largest nodule was 27 (IQR: 18–35) mm.
Table 2 shows the detailed intraoperative events. The open
approach was used in 52 (66%) patients, and the laparoscopic
approach was used in 27 (34%) patients, with 1 case (4%) of
conversion to the open approach. The latter was evaluated in the
laparoscopic group on an intent-to-treat basis. Minor LR was
performed in 72% (n = 65) of patients. Eleven (14%) patients
needed intraoperative blood transfusion.−
‡ Associated procedures included partial hepatectomy (3 patients), local destruction
(2 patients), portal thrombectomy (1 patient), opening of the diaphragm (1 patient),
portal thrombectomy, and opening of the diaphragm (1 patient).Ninety-day mortality and morbidity
Overall, the 90-day mortality rate was 6% (n = 5; Table 3); 3 and 2
patients had major andminor resections, respectively. All patientsTable 1. Baseline clinical, laboratory and tumour characteristics of the
study population.
Variables Study population (79 patients)
Age (years) 65 (59–70)
Male gender, yes 65 (82)
Body mass index (kg/m2) 29 (25–31)
ASA score >2 38 (48)
Previous treatment before resection 18 (23)
Hepatectomy 2 (3)
Local destruction 2 (3)
TACE 12 (15)
Sorafenib 2 (3)
Child-Pugh class (A/B) 78 (99)/1 (1)
HVPG (mmHg) 12 (11–15)
Surrogate criteria of CSPH 31 (39)
Oesophageal varices 26 (33)
Splenomegaly and thrombopenia* 12 (15)
Viral infection 50 (63)
MELD score 8 (6–9)
Pre-resection blood tests
Serum albumin (g/L) 40 (37–43)
Serum total bilirubin (lmol/L) 12 (8–18)
Platelet (/105/ml) 133 (101–167)
Serum creatinine (lmol/L) 83 (67–92)
AFP (ng/ml) 8 (4–38)
Multiple nodules 13 (16)
Maximum tumour size (mm) 27 (18–35)
Resection margin (mm) 5 (2–10)
Satellite nodules 9 (11)
Macrovascular invasion 3 (4)
Microvascular invasion 25 (32)
Poor differentiated tumours 5 (6)
Results are presented as median (IQR) or n (%).
AFP, a-fetoprotein; ASA, American Society of Anesthesiologists; CSPH, clinically sig-
nificant portal hypertension; HVPG, hepatic venous pressure gradient; MELD, Model
for End-Stage Liver Disease; LLR, laparoscopic liver resection; TACE, transarterial
chemoembolisation.
* Splenomegaly >120 mm in diameter and platelet count <100,000/ml.
JHEP Reports 2021had postoperative liver decompensation, and 3 had persistent liver
decompensation at 3 months. Causes of death included persistent
liver decompensation in 3 patients (liver failure in 2 patients and
ascites in 1 patient), new onset of ascites in 1 patient, and post-
operative diffuse portal vein thrombosis in 1 patient.
The details of postoperative complications are shown in
Table 3. Overall, 53 of 79 patients developed postoperative
complications (morbidity rate = 67%) with a median CCI of 8.7
(0–30). Major complications (CCI >−26.2) occurred in 21 (27%)
patients.
Postoperative ascites, liver failure, haemorrhage, and bile
leakage occurred in 25 (3%), 6 (8%), 6 (8%), and 3 (4%) patients,
respectively. The median hospital stay was 14 (IQR: 8–19) days.
Nine (10%) patients needed readmission.
Postoperative liver decompensation
Overall, 28 (35%) patients developed at least 1 sign of post-
operative liver decompensation, including ascites in 25 patients,
jaundice in 6, and encephalopathy in 3. Among them, 5 (18%,
5/28) died within 90 days of surgery (see later). An increased
preoperative HVPG value [p = 0.004; odds ratio (OR) = 1.5; 95%
CI = 1.1–1.9], increased elevated preoperative serum total bili-
rubin (p = 0.02; OR = 1.1; 95% CI = 1.0–1.3), and open approach
(p = 0.03; OR = 8.7; 95% CI = 1.2–63.9) were independent pre-
dictors of postoperative liver decompensation (Table 4).
At 3 months following resection, 8 (10%) patients had
persistent liver decompensation: 5 had refractory ascites, 2 had
jaundice and ascites, and 1 had encephalopathy. Four (50%, 4/8)
of them died within 12 months following surgery.
Textbook outcomes
A textbook outcome was achieved in 27 (34%) patients. The
distributions of each textbook outcome criterion are shown in3vol. 3 j 100190
Table 3. Short and long-term outcomes.
Outcome N =79
Any perioperative morbidity 53 (67)
CCI 8.7 (0–28)
Severe morbidity (CCI >−26.2) 21 (27)
Combined medical, surgical and/or liver-related
complications
16 (20)
Medical complications only 14 (18)
Infection 14 (18)
Cardiac and respiratory 14 (18)
Acute kidney injury 4 (5)
Surgical complication only 7 (9)
Wound complications 3 (4)
Haemorrhage 6 (8)
Fluid collections requiring percutaneous drainage 10 (13)
Surgical reintervention 2 (3)
Liver-related complications only 16 (20)
Ascites 25 (3)
Biliary fistula 3 (4)
Encephalopathy 3 (4)
Liver failure 6 (8)
Postoperative liver decompensation 28 (35)
Persistent liver decompensation at 3 months 8 (10)
Jaundice and ascites 2 (3)
Ascites 5 (6)
Encephalopathy 1 (1)
Postoperative hospital stay (days) 8 (6–15)
Mortality
90-day mortality 5 (6)
1-year mortality 9 (11)
HCC recurrence 36 (46)
Timing (months following resection) 22 (1–43)
Intrahepatic/extrahepatic/both recurrence 33 (92)/2 (6)/1 (2)
Curative treatment* 14 (39)
Treatment type†
Liver transplantation 3 (8)
Re-hepatectomy 2 (6)
Local destruction 9 (25)
TACE 10 (28)
Combination local destruction and chemotherapy 1 (3)
Best supportive care 11 (31)
Postoperative follow-up (months) 39 (18–56)
Results are presented as median (IQR) or n (%).
CCI, Comprehensive Complication Index; TACE, transarterial chemoembolisation.
* Curative treatment included transplantation, surgery and local destruction.
† The most effective treatment was retained when a multimodal management was
implemented.
Research articleFigure 1. In the multivariate analysis, the laparoscopic approach
emerged as the sole independent predictor associated with
textbook outcome (p = 0.004, OR = 5.6; 95% CI = 1.7–18.2;
Table 5). Textbook outcomes were achieved in 63% and 19% (p =
0.0001) of patients who underwent laparoscopic and open LR,
respectively. A textbook outcome was observed in 7% and 40%
(p = 0.02) of patients who underwent major and minor LR,
respectively. A textbook outcome was achieved in 43%, 43%, and
10% (p = 0.02) of patients submitted to surgeries graded as low,
moderate, and high difficulty, respectively. A textbook outcome
was achieved in 56%, 37%, 0%, and 0% of patients with tumours
classified as Barcelona-Clinic Liver Cancer (BCLC) 0, A, B, and C,
respectively (p = 0.01).Long-term oncological outcomes
During the follow-up period, recurrence occurred in 36 (46%)
patients with a median delay of 22 months (IQR: 1–43). The first
recurrence was intrahepatic in most cases (33 patients, 92%).
Curative treatment could be applied in 14 (39%) patients,JHEP Reports 2021including liver transplantation, rehepatectomy, and local
destruction in 8%, 6%, and 25% of patients, respectively.
The 1-, 3-, and 5-year overall survival rates were 89%, 73%,
and 55%, respectively (Figure 2). The 1-, 3-, and 5-year
recurrence-free survival rates were 82%, 62%, and 43%, respec-
tively (Figure 2).Discussion
In the present series, LR for HCC in selected patients with
cirrhosis and actual CSPH, as assessed by HVPG measurement,
was performed with acceptable results not only in terms of
standard medical-centered outcomes, including 90-day mortal-
ity (6%), overall morbidity (67%), and 5-year overall survival
(55%), but also in terms of patient-centered outcomes, with
textbook outcomes achieved in one-third of patients across the
various technical difficulty and BCLC grades. In addition, our
selection criteria increased the number of LRs for HCC by 21%.
The updated EASL guidelines endorse a risk algorithm for
postoperative decompensation following LR for HCC,5 which
includes the hierarchical interaction of three variables in the
following order: presence of PHT; extent of resection; and MELD
score. In these guidelines, CSPH is no longer a formal contrain-
dication for the resection of HCC in patients with cirrhosis,
provided that this is balanced by the extent of LR and liver
function. Importantly, the above-mentioned algorithm was
developed from a series of surgeries all performed with an open
approach, in which CSPH was defined by the presence of indirect
signs for this condition4; however, the laparoscopic approach
per se is acknowledged to decrease the risk of liver surgery,6,8,34
and surrogates of CSPH lack sensitivity and specificity compared
with the HVPG measurement10,11,35,36 and >50% of compensated
patients, as in our study population, with HVPG >−10 mmHg
might have no varices and normal or almost normal platelet
count.36 In this subset of well-selected patients with HVPG >−10
mmHg, some centres, following the guidelines, reported
reasonable surgical and acceptable long-term oncological out-
comes, with postoperative liver decompensation ranging from
6% to 33% and 3-year survival ranging from 72% to 79%.28,37,38
Clearly, the present series only included selected patients
with good general condition [52% with American Society of
Anesthesiologists (ASA) score <2], a preserved liver condition
(99% with Child-Pugh A, median MELD score of 8), and favour-
able tumour biology (84% with single nodules, median tumour
size of 27 mm, median AFP level = 8 ng/ml). Nevertheless, it
comprised a full spectrum of the three aspects of tumours across
the BCLC classification, of the magnitude of surgical procedures
from non-anatomical to major resections, and of technical
complexity. The mortality and morbidity rates as well as the
postoperative liver decompensation incidence achieved here do
not require further comment, because they were concordant
with those reported by other series including patients with CSPH
defined by HVPG >−10 mmHg.
2,28,37,38 We consider that the
comparison of these results to those obtained when the criteria
per the guidelines to proceed for surgery are met, is at least
debatable, if even clinically sound, because these guidelines
target both the best perioperative outcome and longest survival
time possible following surgery for the ideal surgical candidates.
We acknowledge the value of guideline recommendations and
expected results, but we also consider it meaningful to clinicians
and patients to provide a comparison between surgical man-
agement and the best non-surgical management for clinical4vol. 3 j 100190
Table 4. Uni- and multivariable analysis of variables associated with postoperative liver decompensation.
Variable
Postoperative liver decompensation
Univariate p value Multivariate p value [OR (95% CI)]Yes (n = 28) No (n = 51)
Age (years) 66 (59–70) 65 (58–70) 0.90
Male sex 24 (86) 41 (80) 0.55
BMI (kg/m2) 28 (22–31) 29 (25–32) 0.24
ASA score >2 11 (39) 27 (53) 0.25
Viral aetiology 21 (75) 29 (57) 0.11
Previous treatment 8 (29) 10 (20) 0.36
Repeat hepatectomy 0 (0) 2 (4) 0.29
Child-Pugh class B 0 (0) 1 (2) 0.46
HVPG (mmHg) 14 (12–20) 11 (10–13) <0.0001 0.004 [1.5 (1.1–1.9)]
Indirect signs of CSPH 13 (46) 18 (35) 0.33
Oesophageal varices 11 (39) 15 (29) 0.37
Splenomegaly and thrombopenia 5 (18) 7 (14) 0.62
MELD score 8 (6–10) 8 (6–9) 0.40
Creatinine (lmol/L) 75 (67–95) 83 (69–92) 0.60
Serum total bilirubin (lmol/L) 16 (11–23) 11 (8–15) 0.002 0.02 [1.1 (1.0–1.3)]
Serum albumin (g/L) 37 (34–41) 41 (38–44) 0.03 0.93
Platelet (105/mm3) 130 (95–164) 135 (104–167) 0.36
Portal vein embolisation 4 (14) 1 (2) 0.03 0.99
Major resection 9 (32) 5 (10) 0.01 0.67
Open approach 23 (82) 29 (57) 0.02 0.03 [8.7 (1.2–63.9)]
Anatomical resection 18 (64) 26 (51) 0.25
Associated procedures 4 (14) 4 (8) 0.36
Inflow clamping 23 (82) 43 (84) 0.80
Operative time (min) 230 (184–344) 240 (180–300) 0.34
Blood transfusion 8 (29) 3 (6) 0.005 0.20
High grade of technical difficulty 17 (61) 18 (35) 0.03 0.33
Results are presented as median (IQR) or n (%).
ASA, American Society of Anesthesiologists; CSPH, clinically significant portal hypertension; HVPG, hepatic venous pressure gradient; MELD, Model for End-Stage Liver
Disease; OR, odds ratio.decision-making and on an intent-to-treat basis. Given the
paucity of data published, the natural outcome of patients
treated on an intent-to-treat basis is not well known, but median
survival has been reported to be <36 months.1
Textbook outcome is a composite endpoint that integrates a
selection of relevant peri- and postoperative outcomes, and repre-
sents the ideal postoperative course following a surgical procedure.
Evaluating textbook outcome among patients with cirrhosis, CSPH
and HCC is particularly interesting not only because it gives an
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Fig. 1. Distribution of each textbook outcome criterion.
JHEP Reports 2021because it shows that ideal perioperative outcomes can be achieved
in these non-ideal patients. In the present series, a textbook
outcomewas achieved overall in one-third of patients, including 7%
and 23% of those who underwent major hepatectomies and mod-
erate/highly complex surgery, respectively. This composite criterion
is oneof the latestpatient-centeredoutcomes39,40 added to improve
the vital patient–doctor decision process41 to proceed for surgery,
including the provision of tool aids for decisions, recommendations
from guidelines and consensus conferences.
Interestingly, the laparoscopic approach was the sole inde-
pendent predictor of a textbook outcome in the present series of
a priori high-risk patients. Unsurprisingly, patients with very/
early HCC were more likely to achieve a textbook outcome than
were those with more advanced tumour stages (BCLC B/C). Pa-
tients with minor and low-difficulty LRs were also more likely to
achieve a textbook outcome than were those with major and
moderate/high-difficulty LRs. Overall, the textbook rate observed
in the present series was lower than that reported in a previous
series (62.3%).32 There are several possible reasons for this dif-
ference, including the baseline characteristics of the patients
(70.1% with ASA score <2, 36.2% with only cirrhosis) and the
definition of the textbook outcome itself.
This study was retrospective. However, the data were ob-
tained from a multicentric prospectively maintained database,
making this series of LRs in patients with cirrhosis and confirmed
CSPH the largest available. Given that the main objective of this
study was to reappraise the outcomes in this highly selected
group of patients in terms of the effects of the laparoscopic
surgery and the assessment of textbook outcome, rather than to
confirm what previous studies had already shown in terms of
feasibility and safety, we did not compare our study population
with patients with HVPG <10 mmHg as controls. The most5vol. 3 j 100190
Table 5. Uni- and multivariable analysis of variables associated with a textbook outcome.
Variable
Textbook outcomes
Univariate p value Multivariate p value [OR (95% CI)]Yes (n = 27) No (n = 52)
Age (years) 64 (59–71) 66 (44–69) 0.59
Male sex 21 (78) 44 (85) 0.45
Body mass index (kg/m2) 27 (24–30) 30 (26–32) 0.19
ASA score >2 14 (52) 24 (46) 0.63
Virus-related cirrhosis 16 (59) 34 (65) 0.59
Previous treatment 4 (15) 14 (27) 0.22
Repeat hepatectomy 1 (4) 1 (2) 0.63
Child-Pugh class B 0 (0) 1 (2) 0.47
HVPG (mmHg) 11 (10–14) 12 (11–16) 0.13
Indirect signs of CSPH 12 (44) 19 (37) 0.49
Oesophageal varices 10 (37) 16 (31) 0.57
Splenomegaly and thrombopenia 4 (15) 8 (15) 0.95
MELD score 8 (6–9) 8 (6–9) 0.57
Creatinine (lmol/L) 84 (70–91) 78 (67–97) 0.48
Total Bilirubin (lmol/L) 11 (8–15) 14 (9–19) 0.06 0.21
Albumin (g/L) 42 (39–44) 39 (36–42) 0.05 0.43
Platelet (105/mm3) 127 (96–167) 134 (104–164) 0.30
Portal vein embolisation 0 (0) 5 (10) 0.10 0.99
Major resection 1 (4) 13 (25) 0.02 0.70
Laparoscopic approach 10 (37) 42 (81) 0.0001 0.003 [7.2 (2.0–25.6)]
Anatomical resection 14 (52) 30 (58) 0.62
Associated procedures 1 (4) 7 (13) 0.17
Inflow clamping 6 (22) 7 (13) 0.32
Operative time (min) 230 (180–293) 240 (188–334) 0.17
High grade of technical difficulty 8 (30) 27 (52) 0.06 0.13
Results are presented as median (interquartile range) or n (%).
ASA, American Society of Anesthesiologists; CSPH, clinically significant portal hypertension; HVPG, hepatic venous pressure gradient; MELD, Model for End-Stage Liver
Disease; OR, odds ratio.
Research articleappropriate control group would be patients with HVPG >−10
mmHg who did not undergo surgery. Ideally, a randomised
controlled trial comparing resection to non-resection manage-
ment in the selected population (i.e. in patients with 10 mmHg <
HVPG <30 mmHg, good general status and preserved liver and
kidney function, and low MELD score) would be performed.
However, considering the results obtained here, we are not
convinced that this trial would be ethical, if ever feasible,
because of the limited number of eligible patients.N° at risk
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Fig. 2. Overall survival (OS) and recurrence-free survival (RFS) rates of the
study population.
JHEP Reports 2021Liver transplantation is the best available treatment for pa-
tients with HCC and PHT, but the shortage of liver grafts, strict
inclusion criteria (e.g. age, comorbidities, and tumour charac-
teristics) together with the risks of dropout from the waiting list
because of PHT42 could preclude access for a large number of
candidates. Interestingly, 56% (n = 44) of patients in the present
series were initially transplantable based on the acknowledged
transplantation criteria.
The low rate of posthepatectomy liver failure (8%, n = 6 in this
series)methodologically hampered a soundmultivariate analysis to
identify the independent predictors of thismajor complication. This
eventwas rare in this series comparedwith others, again because of
the stringent selection of candidates for surgery. Finally, the number
of patients did not allow us to perform a subanalysis regarding a
potential effect of centre difference or era difference on outcomes.Conclusions
Patients with cirrhosis, HCC, and measured CSPH (i.e. HVPG >−10
mmHg) can be resected with acceptable rates of mortality,
morbidity, liver decompensation, and even a textbook outcome.
These results can be achieved in selected patients with preserved
liver function, good general status, and sufficient remnant liver
volume.
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